Monopar CFO Kim Tsuchimoto retiring; Karthik Radhakrishnan appointed successor

Monopar Therapeutics

CFO Kim Tsuchimoto retires effective June 30, 2024 after 35+ years; remains on Board.
Karthik Radhakrishnan appointed CFO, principal accounting and financial officer effective July 1, 2024.
Radhakrishnan receives $384,800 annual salary, 35% target bonus, and options for 125,000 shares vesting over 4 years.
Radhakrishnan has over 20 years experience; previously CFO of Opexa Therapeutics, founder of Titania Partners.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kim R. Tsuchimoto

Chief Financial Officer

MNPR · Monopar Therapeutics

Effective: 2024-06-30
Successor: Karthik Radhakrishnan
Filed: May 24, 2024, 7:59 PM ET

Effective June 30, 2024, after a career spanning more than 35 years, Kim R. Tsuchimoto, the Chief Financial Officer of Monopar Therapeutics Inc. (“Monopar” or the “Company”), will be retiring.

Appointed

Karthik Radhakrishnan

Chief Financial Officer

MNPR · Monopar Therapeutics

Effective: 2024-07-01
Filed: May 24, 2024, 7:59 PM ET

On May 23, 2024, the Company’s Board of Directors appointed, Karthik Radhakrishnan, age 53, to succeed Ms. Tsuchimoto as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective July 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kim R. Tsuchimoto departed as Chief Financial Officer at Monopar Therapeutics.

Action: retiring
Role: Chief Financial Officer

Exact text from the filing

Effective June 30, 2024, after a career spanning more than 35 years, Kim R. Tsuchimoto, the Chief Financial Officer of Monopar Therapeutics Inc. (“Monopar” or the “Company”), will be retiring.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Karthik Radhakrishnan was appointed as Chief Financial Officer at Monopar Therapeutics.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 23, 2024, the Company’s Board of Directors appointed, Karthik Radhakrishnan, age 53, to succeed Ms. Tsuchimoto as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective July 1, 2024.

View on SEC.gov

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-24-018249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.